JOINT FILING AGREEMENT

Exhibit 1

JOINT FILING AGREEMENT

The undersigned hereby agree that the Schedule 13D with respect to the Common Stock of RegeneRx Biopharmaceuticals, Inc. dated as of July 6, 2023, is, and any amendments thereto signed by such of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

ESSETIFIN S.P.A.			XXXXXX XXXXXXX
By:	/s/ Xxxxxx Xxxxxxxx		By:	/s/ Xxxxxx Xxxxxxxx
Name:	Xxxxxx Xxxxxxxx		Name:	Xxxxxx Xxxxxxxx
Title:	Chief Executive Officer		Title:	Attorney-in-fact
Date:	July 6, 2023		Date:	July 6, 2023
XXXXX XXXXXXX			XXXXXXX XXXXXXX PRETA
By:	/s/ Xxxxx Xxxx		By:	/s/ Xxxxxx Xxxxxxxx
Name:	Xxxxx Xxxx		Name:	Xxxxxx Xxxxxxxx
Title:	Attorney-in-fact		Title:	Attorney-in-fact
Date:	July 6, 2023		Date:	July 6, 2023
XXXXXX XXXXXXX			APTAFIN S.P.A.
By:	/s/ Xxxxxx Xxxxxxxx		By:	/s/ Xxxxxxxx Xxxxxxxx
Name:	Xxxxxx Xxxxxxxx		Name:	Xxxxxxxx Xxxxxxxx
Title:	Attorney-in-fact		Title:	Chief Executive Officer
Date:	July 6, 2023		Date:	July 6, 2023
XXXXXXXXX XXXXXXX			APTAFIN FINANCE SA
By:	/s/ Xxxxxx Xxxxxxxx		By:	/s/ Xxxxxxx Xxxxxxxx
Name:	Xxxxxx Xxxxxxxx		Name:	Xxxxxxx Xxxxxxxx
Title:	Attorney-in-fact		Title:	Director
Date:	July 6, 2023		Date:	July 6, 2023
			By:	/s/ Xxxxxxx Xxxxxxx
			Name:	Xxxxxxx Xxxxxxx
			Title:	Director
			Date:	July 6, 2023